Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Chronic Graft Versus Host Disease

In brief

The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as part of first-line therapy for cGVHD.

Key facts

Study ID
NCT02701634
Run by
Gilead Sciences
People needed
66
Starts
2016-05-27
Expected to finish
2018-03-06
Last updated by the study team
2018-12-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.